Aurinia Pharmaceuticals(AUPH)2025-05-12 10:05Financial Performance - For the three months ended March 31, 2025, net product sales were 48.1 million in the same period of 2024[66]. - Total revenue for the three months ended March 31, 2025, was 50.3 million in the same period of 2024[69]. - Gross margin for the three months ended March 31, 2025, was 86%, compared to 85% in the same period of 2024[78]. Cash Flow and Position - Cash flow provided by operating activities was (18.6) million in the same period of 2024[67]. - As of March 31, 2025, the cash position was 358.5 million at December 31, 2024[68]. - Excluding restructuring payments, cash flow generated from operations was 12.4 million for the three months ended March 31, 2025[88]. - Future operations are expected to be funded by existing cash or cash generated from operations[89]. - Additional capital may be raised through equity or debt financings if necessary, but favorable terms are not guaranteed[90]. Expenses - Selling, general and administrative (SG&A) expenses decreased to 20.3 million for the three months ended March 31, 2025, from 47.7 million in the same period of 2024[80]. - Research and development (R&D) expenses increased to 5.7 million for the three months ended March 31, 2025, compared to 1.5 million for the three months ended March 31, 2025, down from 6.7 million in the same period of 2024[86]. - The company expects SG&A expenses to remain low in 2025 as it realizes the benefits of strategic restructuring efforts[81]. - The company anticipates an increase in R&D expenses as it advances the AUR200 program through clinical development[84]. Share Repurchase - The company repurchased 5.8 million common shares for 47.4 million during the three months ended March 31, 2025[88]. Accounting Policies - There have been no material changes to critical accounting policies or market risk disclosures since the Annual Report for the year ended December 31, 2024[91][94].